Skip header and navigation

3 records – page 1 of 1.

Document Type
Rapid Review
Review Code
INF031801v017 RR
Question Submitted
March 18, 2021
Date Completed
November 26, 2021
Status
5. Updated review
Research Team
Infectious Disease
Document Type
Rapid Review
Review Code
INF031801v017 RR
Question Submitted
March 18, 2021
Date Completed
November 26, 2021
Status
5. Updated review
Research Team
Infectious Disease
Updated Key Findings
November 16, 2021
Centers for Disease Control and Prevention (CDC) recommended that any individuals who develop myocarditis/pericarditis after a dose of an mRNA COVID-19 vaccine should defer receiving a subsequent dose until additional safety data are available.
On 9th November, 2021, the CDC allows mix and match of booster shots in USA.
National Advisory Committee on Immunization (NACI) recommended boosters for other high-risk groups, including people 70 years of age and older and front-line health care workers who had a short period of time between their first two shots.
NACI also recommended boosters for people who received two doses of the Astra Zeneca vaccine, as the mRNA vaccines appear to offer better protection.
On 4th November, 2021, the United Kingdom became the first country to approve Pfizer’s competitorOK competitor Merck's COVID-19 pill, which is already under review at the Food and Drug Administration (FDA) after showing strong initial results. Other antivirals are under consideration including an agent from Pfizer (Paxlovid). While promising, caution should be taken with interpreting data from oral antivirals as currently, no published data exist and much conclusions are drawn off grey literature .
India’s Covaxin covid 19 vaccine by Bharat Biotech reported a vaccine effectiveness of 77.8% from a clinical trial. , 2021, a CDC reported vaccine efficacy of 90.9% with primary data from one phase II/III clinical trial in preventing symptomatic, laboratory-confirmed COVID-19 in children aged 5–11 years with or without evidence of previous SARS-CoV-2 infection.
Key Findings
November 2, 2021
October 21st, 2021 Pfizer Inc. and BioNTech announced results from a Phase 3 randomized, controlled trial evaluating the efficacy and safety of a 30-µg booster dose of the Pfizer-BioNTech COVID-19 with a relative vaccine efficacy of 95.6%.
On 21st October, 2021, the advisory panel for the Centers for Disease Control and Prevention (CDC) said people who received Moderna and Johnson & Johnson (J&J) COVID-19 vaccines should receive a booster dose, and should continue with the original vaccine they recieved.
NACI’s latest guidelines suggest provinces should offer boosters to Canadians who received two doses of the Oxford-AstraZeneca vaccine or one dose of the Johnson & Johnson vaccine.
The US Food and Drug Administration (FDA) vaccine advisory group on 26th October 2021 approved the emergency use of the Pfizer-BioNTech COVID-19 vaccine for children ages 5 to 11 at a reduced dosage from the stanard dosing available for those over 12.
Therapeutic Goods Administration (Australia) has provisionally approved a third dose of the Pfizer (Comirnaty) vaccine for individuals 18 years or older. Pfizer (Comirnaty) is recommended as a single booster dose, irrespective of the primary COVID-19 vaccine used.
On 29th October, 2021, NACI issued new guidance "strongly" recommending booster shots for seniors 80 and older.
A survey at University of Oxford, UK, found that social media played a part in children aged 9 to 18 being more undecided than their older counterparts.
A report by the CDC found that the effectiveness of 2 doses of Pfizer-BioNTech vaccine against COVID-19 hospitalization was 93% during the period of B.1.617.2 (Delta) variant dominance among children and adolescents aged 12–18 years.
Category
Epidemiology
Infection Prevention and Control
Subject
Vaccines
Immunity
Clinical Presentation
Infection Prevention and Control
Population
All
Clinical Setting
Community
ICU
Medicine Unit
Primary care
Public Health
Priority Level
Level 3 Two weeks (14 days)
Cite As
Jagwani, M; Lee, S; Shumilak, G; Reeder, B; Groot, G; Hernandez, L; Howell-Spooner, B; Miller, L. How effective are COVID-19 vaccines? 2021 Nov 26. Document no.: INF031801v017 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 96 p. (CEST rapid review report)
Review History
INF031801v16 RR: November 12, 2021
INF031801v15 RR: October 28, 2021
INF031801v014 RR: October 16, 2021
INF031801v013 RR: September 24, 2021
INF031801v012 RR: September 10, 2021
INF031801v010 RR: August 25, 2021
INF031801v9 RR: August 23, 2021
INF031801v8 RR: August 9, 2021
INF031801v7 RR: July 20, 2021
INF031801v6 RR: July 2, 2021
INF031801v5 RR: June 22, 2021
INF031801v4 RR: June 3, 2021
INF031801v3 RR: May 24, 2021
INF031801v2 RR: May 14, 2021
INF031801 RR: March 31, 2021
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
EPM210602 RR
Question Submitted
June 22, 2021
Date Completed
July 12, 2021
Status
3. Completed
Research Team
Epidemiology & Modelling
Document Type
Rapid Review
Review Code
EPM210602 RR
Question Submitted
June 22, 2021
Date Completed
July 12, 2021
Status
3. Completed
Research Team
Epidemiology & Modelling
Key Findings
Long COVID-19 is likely to increase healthcare demands across the health system, including emergency departments, hospital admissions, primary care visits, specialists appointments, and home care and rehabilitation services.
The clinical care burden of long COVID-19 is the greatest in the first 3 months after testing and is likely to place the greatest demand on primary care services.
Patients with severe COVID-19 illness are more likely to place longer-term demands (4-6 months) on specialist care due to respiratory, circulatory, endocrine, metabolic, psychiatric and unspecified conditions.
Category
Clinical Presentation
Epidemiology
Subject
Long Covid
Health Planning
Clinical Presentation
Population
All
Clinical Setting
Ambulatory
Community
Emergency
ICU
Long Term Care
Medicine Unit
Primary care
Public Health
Priority Level
Level 1 2-3 days
Cite As
McLean, M; Williams-Roberts, H; Reeder, B; Howell-Spooner, B; Ellsworth, C. What are long COVID's demands on the healthcare system, and its severity of the illness? 2021 Jul 12, Document no.: EPM210602 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 23 p. (CEST rapid review report).
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
EPM210601 RR
Question Submitted
June 22, 2021
Date Completed
July 9, 2021
Status
3. Completed
Research Team
Epidemiology & Modelling
Document Type
Rapid Review
Review Code
EPM210601 RR
Question Submitted
June 22, 2021
Date Completed
July 9, 2021
Status
3. Completed
Research Team
Epidemiology & Modelling
Key Findings
The frequency of Long COVID symptoms varies widely across studies based on populations studied, duration of follow up and methods of assessment of symptoms.
It is estimated that 1 in 50 persons experience Long COVID symptoms after 12 weeks; however, higher estimates up to 80% have been reported in studies with a greater proportion of persons who were previously hospitalized. A recent study of a mixed cohort of 96 persons found that only 22.9% had no symptoms at 12 months post diagnosis.
A wide range of symptoms affecting multiple organ systems has been reported. For many persons symptoms improve over time while others experience persistent and/or new symptoms. Among studies with the longest duration of follow up, the most frequently reported symptoms included fatigue (up to 65%), dyspnea (up to 50%), headache (up to 45%), anosmia/ageusia (up to 25%), cognitive memory/concentration (up to 39.6%) and sleep disorders (up to 26%).
Few studies estimated the duration of symptoms with estimates ranging from 2.2% for 6 months and 27% for 7-9 months.
The mechanism(s) leading to Long COVID remain unclear but those experiencing post acute sequelae tend to be older, have a greater number of symptoms during the acute phase of illness or manifest specific symptoms and live with multiple comorbid conditions such as obesity.
The lack of consensus on a definition of Long COVID contributes to marked variations in robust prevalence estimates.
Category
Clinical Presentation
Epidemiology
Subject
Long Covid
Symptoms
Clinical Presentation
Population
All
Clinical Setting
Ambulatory
Community
ICU
Long Term Care
Medicine Unit
Primary care
Public Health
Priority Level
Level 1 2-3 days
Cite As
Williams-Roberts, H; Groot, G; Reeder, B; Howell-Spooner, B; Ellsworth, C. What is the incidence and duration of Long COVID cases? 2021 Jul 09, Document no.: EPM210601 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 19 p. (CEST rapid review report).
Related Documents
Documents
Less detail